Solid Biosciences INC Form 4 insider transactions

Solid Biosciences Chief Operating Officer David T. Howton reported the vesting of performance and restricted stock units, along with the grant of new options and RSUs, and a non-discretionary sale to cover taxes.

Solid Biosciences' Chief Technology Officer, Paul Herzich, reported the vesting and conversion of equity awards, alongside a tax-related stock sale.

Solid Biosciences Director Ilan Ganot reported significant equity transactions, including new stock options and RSU grants, alongside the vesting and conversion of existing RSUs.

Solid Biosciences Director Ilan Ganot reported the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover withholding taxes.

Solid Biosciences CFO Kevin Tan reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding, not a discretionary trade.

Solid Biosciences Director Ian F. Smith converted restricted stock units into common shares and received new stock options and restricted stock unit grants.

Ilan Ganot, a Director at Solid Biosciences, reported his wife's acquisition of common stock from RSU vesting and subsequent sale to cover tax obligations.

Solid Biosciences' Chief Operating Officer, David T. Howton, reported the vesting of 13,051 restricted stock units and a subsequent sale of 4,932 shares to cover tax obligations under a pre-arranged 10b5-1 plan.

Solid Biosciences Inc. CEO Alexander Cumbo reported the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations.

Solid Biosciences Chief Regulatory Officer Jessie Hanrahan sold 4,483 shares of common stock at $5.11 per share to cover tax obligations following RSU vesting.

Solid Biosciences' Chief Technology Officer, Paul Herzich, sold 2,701 shares of common stock at $5.11 per share to cover tax obligations following the vesting of restricted stock units.

Solid Biosciences Inc. Director Ilan Ganot sold 3,278 shares of common stock for a weighted average price of $4.12 per share under a pre-arranged trading plan.

Solid Biosciences Chief Medical Officer Gabriel Brooks reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.

Solid Biosciences Director Ian F. Smith converted 4,573 restricted stock units into common stock, increasing his direct beneficial ownership.

Solid Biosciences Director Ilan Ganot was granted 37,500 stock options and 18,750 restricted stock units, vesting over four years.

Solid Biosciences Inc. Chief Operating Officer David T. Howton received significant equity awards, including stock options and restricted stock units, vesting over four years.

Solid Biosciences' CFO and Treasurer, Kevin Tan, was granted 187,500 equity awards, comprising stock options and restricted stock units, effective August 14, 2025.

Solid Biosciences' Chief Technology Officer, Paul Herzich, was granted 150,000 equity awards, comprising 100,000 stock options and 50,000 restricted stock units, vesting over four years.

Solid Biosciences' Chief Medical Officer, Gabriel Brooks, was granted 142,500 stock options and 71,250 restricted stock units, vesting over four years.

Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, was granted 142,500 stock options and 71,250 restricted stock units.

Solid Biosciences Inc. President and CEO Alexander Cumbo received a grant of 337,500 stock options and 168,750 restricted stock units.

Solid Biosciences Inc. Director Ian F. Smith converted 4,573 restricted stock units into common stock, increasing his direct beneficial ownership of common shares to 122,119.

Solid Biosciences Inc. Director Georgia Keresty was granted 77,500 stock options with an exercise price of $4.58, as disclosed in a recent SEC Form 4 filing.

Solid Biosciences Inc. Director Adam Leo Stone was granted 77,500 stock options with an exercise price of $4.58, as disclosed in a recent SEC Form 4 filing.

Perceptive Advisors LLC, a 10% owner and director of Solid Biosciences Inc., reported the acquisition of 77,500 director stock options with an exercise price of $4.58, granted to Adam Stone for his board service.

Solid Biosciences Inc. Director Ian F. Smith was granted 77,500 stock options with an exercise price of $4.58, aligning his interests with shareholder value.

Solid Biosciences Inc. Director Martin I Freed was granted 77,500 stock options with an exercise price of $4.58, vesting fully within one year or upon a change of control.

Solid Biosciences Inc. Director Sukumar Nagendran was granted 77,500 stock options with an exercise price of $4.58, vesting on the earlier of the one-year anniversary of the grant date or the next annual meeting.

Solid Biosciences Inc. Director Clare Kahn was granted 77,500 stock options with an exercise price of $4.58, vesting based on time or change of control events.

Solid Biosciences Inc. Director Ilan Ganot was granted 77,500 stock options with an exercise price of $4.58, vesting on the earlier of the one-year anniversary of the grant date or the next annual meeting.